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Glioblastoma (GBM) stem cells (GSCs) represent tumor-propagating cells with stem-like characteristics (stemness) that
contribute disproportionately toGBMdrug resistance and tumor recurrence. Understanding themechanisms supporting
GSC stemness is important for developing therapeutic strategies for targeting GSC-dependent oncogenic mechanisms.
UsingGBM-derivedneurospheres,we identified thecell surface tetraspanin familymemberCD151asanovel regulator of
glioma cell stemness, GSC self-renewal capacity,migration, and tumor growth. CD151was found to be overexpressed in
GBM tumors and GBM neurospheres enriched in GSCs. Silencing CD151 inhibited neurosphere forming capacity,
neurosphere cell proliferation, andmigration and attenuated the expression of markers and transcriptional drivers of the
GSC phenotype. Conversely, forced CD151 expression promoted neurosphere self-renewal, cell migration, and
expression of stemness-associated transcription factors. CD151 was found to complex with integrins α3, α6, and β1
in neurosphere cells, and blocking CD151 interactions with integrins α3 and α6 inhibited AKT phosphorylation, a
downstream effector of integrin signaling, and impaired sphere formation and neurosphere cell migration. Additionally,
targetingCD151 in vivo inhibited the growth of GBMneurosphere-derived xenografts. These findings identify CD151 and
its interactions with integrins α3 and α6 as potential therapeutic targets for inhibiting stemness-drivingmechanisms and
stem cell populations in GBM.
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Glioblastoma (GBM) is the most common and aggressive brain
malignancy. Despite advances in therapy, improvement in overall
survival has been limited. Patients with GBM almost uniformly
experience relapse and have a median survival time of only 15 to 20
months despite aggressive treatment with surgery, radiation, and
chemotherapy [11,35]. GBM recurrence appears to be dispropor-
tionately dependent upon tumor-propagating GBM stem cells
(GSCs), which comprise a minority population of highly tumorigenic
cells that display stem cell properties (i.e., stemness), including the
ability to self-renew as spheres and the capacity to differentiate into
multiple neural lineages [15,20,29,33,44,45]. Most importantly,
GSCs efficiently propagate tumor xenografts that recapitulate the
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when implanted orthotopically [29,51]. These cells use microenvir-
onment-dependent and -independent mechanisms to promote tumor
angiogenesis, recurrence, and resistance to cytotoxic therapies
[2,48,50,51]. Understanding the mechanisms supporting GSCs and
their tumor-propagating behaviors is important for developing novel
and more effective therapies.
CD151 is a member of the integral membrane protein superfamily
tetraspanins. CD151 interacts with multiple proteins at the cell
surface, particularly the laminin-binding integrins α3, α6, β1, and
β4, to modulate their intracellular signaling and contribute to the
regulation of cell adhesion and migration [47,53,63]. The tetra-
spanins are also involved in cell proliferation and tissue vascularization
[37,38,60,61]. CD151 is highly expressed in several cancers,
including gastric, endometrial, liver, breast, prostate, and glioma
[9,10,52,55,56]. Its aberrant expression is associated with multiple
oncogenic activities such as metastasis and angiogenesis [8,10].
CD151 has been associated with glioma malignancy, but its
mechanisms of action remain poorly defined. A retrospective
single-institution study of Asian patients with newly diagnosed
GBM found that tumors expressing high levels of CD151 were
associated with shorter progression-free and overall survival [28].
CD151 expression has been associated with a network of oncogenic
myc-interacting genes in glial malignancies [5]. Rao Malla et al. [40]
have implicated CD151 in the mechanism by which urokinase-type
plasminogen activator receptor and cathepsin regulate cell adhesion
and invasion.
A role for CD151 in regulating cell stemness and cancer stem cells
remains undefined. Yin et al. [58] found that CD151 knockout
increased the differentiation potential of mammary luminal stem and
progenitor cell subtypes, suggesting a role in modulating mammary
cell multipotency and differentiation signals. We recently reported a
potentially related finding that CD151 is among a network of genes
that are repressed by KLF9, a transcription factor that drives GSC
differentiation [27,59]. High CD151 expression has been found to
mark tumor-propagating prostate cells and CD133+ tumorigenic
colon cancer cell lines [18,39]. Furthermore, integrin α6, which
marks and regulates GBM stem cells, is known to associate with cell
surface CD151 [27,59]. There are currently no reports directly
linking CD151 expression and/or function to tumor-propagating
GSCs.
It is within this context that we investigated the expression and
function of CD151 in tumor-propagating GSCs. CD151 was found
to be highly expressed in glial tumors and GBM neurosphere isolates.
Silencing endogenous CD151 inhibited glioma cell stemness and
GSC self-renewal, migration, and xenograft growth. Transgenic
CD151 expression enhanced these phenotypic properties. CD151
was found to associate with integrins α3, α6, and β1 in GSCs, and
blocking CD151 integrin interactions inhibited sphere formation,
migration, and activation of downstream integrin signaling. Together,
these results identify CD151 and direct interactions between CD151
and integrins as potential therapeutic targets in GSCs.
Materials and Methods
Reagents
All reagents were purchased from Sigma-Aldrich unless otherwise
stated. Doxycycline (Dox) was diluted to a concentration of 1 μg/ml
in cell culture medium as a working concentration. In all experiments,the final DMSO concentration was b0.1%, which had no
demonstrable effect on neurosphere cultures. Laminin was diluted
to 10 μg/ml as a working concentration unless otherwise indicated.
Cell Culture
Human GBM neurosphere lines 0913 (GBM1A) and 0627
(GBM1B) were originally established by Vescovi and colleagues [15]
and further characterized by us [31,49,59]. The 1123 (M1123) and
146 (P146) neurosphere lines were derived from high-grade glioma
patients and kindly provided by Dr. Nakano (Ohio State University).
Primary GBM neurospheres JHH612 (612) were derived from a
clinical GBM specimen at Johns Hopkins University using the
methods and culture conditions described by Galli et al. [15].
Neurospheres were cultured in serum-free medium supplemented
with epidermal growth factor and fibroblast growth factor and
incubated in 5% CO2/95% air condition at 37°C. Primary
neurospheres were used at less than 10 passages. All human materials
were obtained and used in compliance with The Johns Hopkins
Institutional Review Board.
Lentiviral Transduction
The sequences for CD151 shRNA lentiviral vectors
(TRCN0000300360, TRCN0000300331; Sigma-Aldrich;
V3THS_308057; Thermo Scientific, Hudson, NH, www.
thermoscientific.com) are listed in Supplementary Table S1. N-terminal
3xFLAG-tagged CD151 (3F-CD151) was constructed by high-fidelity
polymerase chain reaction (PCR; Roche, Basel, Switzerland, www.
roche-applied-science.com) and cloned into the pTRIPZ vector
(Thermo Scientific) using AgeI and MluI restriction sites. The
Trans-Lentiviral Packaging System (Thermo Scientific) was used for
lentivirus production. Cells were transfected with lentivirus at a
multiplicity of infection of 5 for 24 hours with TransDux Virus
Infection solution (System Biosciences, Mountain View, CA, www.
systembio.com). Stable GBM neurosphere lines were established by
puromycin selection (1 μg/ml).
Neurosphere Formation Assays
Viable cells (2 × 103/well or 2 × 104/well) were cultured in 48-well
or 6-well plates, respectively. After 7 to 14 days, neurospheres were
fixed in medium with 1% agarose, stained with 1% Wright stain
solution, and counted by computer-assisted morphometry (MCID
software, Cambridge, UK, www.mcid.co.uk) by measuring the
number of neurospheres (N50 μm or N100 μm in diameter, as
indicated) in three random fields per well.
Flow Cytometric Assay
Flow cytometric analysis was performed on unfixed cells stained
with anti-CD133/2(AC133)-phycoerythrin (PE) (Miltenyi Biotec,
Auburn, CA, www.miltenyibiotec.com) or PE-CD151 (BD Biosci-
ences, San Jose, CA, www.bdbiosciences.com) antibody following the
manufacturer’s protocol using a FACSCalibur (BD Biosciences).
Mouse IgG labeled with PE or FITC was used as a control.Western Blot Analysis
Total cellular protein was extracted with radioimmunoprecipitation
assay buffer (Sigma-Aldrich) containing protease and phosphatase
inhibitors (Calbiochem, Billerica, MA, www.calbiochem.com). The
Subcellular Protein Fractionation Kit was used for membrane protein
extraction (Thermo Scientific). SDS-PAGEwas performed with 50 μg of
Neoplasia Vol. 18, No. 3, 2016 Regulation of Glioblastoma Tumor-Propagating Cells Tilghman et al. 187total proteins using 4% to 12% gradient Tris-glycine gels (LI-COR
Biosciences, Lincoln, NE, www.licor.com). Western blot analysis was
performed using the Quantitative Western Blot System, with secondary
antibodies labeled by IRDye infrared dyes (LI-COR Biosciences). The
primary antibodies were anti-CD151, anti-Olig2, anti-FLAG (Santa
Cruz), anti-Sox2, anti-S473-pAkt, anti-total-Akt, anti-integrin α3,
anti-integrin α6, anti-integrin β1 (Cell Signaling), anti-pan Cadherin
(Abcam, Cambridge, MA, www.abcam.com), and anti-β-actin
(Sigma-Aldrich).
Immunoprecipitation
A total of 1 × 107 GBM1A 3F-CD151 cells were treated ± Dox for
48 hours. Cells were lysed in the immunoprecipitation buffer
containing 1% Brij-O1, 20 mM Tris HCl pH 8, 137 mM NaCl, 2
mM EDTA, and protease and phosphatase inhibitors (Calbiochem)
for 1 hour at 4°C on a rotating shaker. Anti-FLAG M2 magnetic
beads (Sigma-Aldrich) or protein A/G magnetic beads as control were
added to the above cell lysate and incubated overnight at 4°C on a
rotating shaker. Beads were collected, and 3F-CD151 bound
complexes were eluted using 3× FLAG peptide (Sigma-Aldrich).
Immunoprecipitates were immunoblotted with primary antibodies.
Immunofluorescence
Neurosphere cells were collected by cytospin onto glass slides and
fixed with 4% paraformaldehyde. Cells were permeabilized by Triton
X-100 and immunostained with anti-CD151 (1:50; Santa Cruz
Biotechnology, Dallas, TX, www.scbt.com), anti-integrin α3 (1:50),
anti-integrin α6 (1:50), and anti-integrin β1 (1:100; Cell Signaling)
antibodies following the protocol from Cell Signaling. Secondary
antibodies were conjugated with Alexa488 or Cy3 (1:250).
Immunofluorescent images were taken and analyzed using the
ZEISS AxioImager M2 Imaging System with Axiovision software
(Zeiss, Thornwood, NY, www.zeiss.com).
Cell Adhesion Assays
Neurosphere cells were dissociated and plated on laminin-coatedwells
for 2 and 6 hours. Adherent cells were fixed with 4% paraformaldehyde
and washed with 0.1% BSA/phosphate-buffered saline. The fixed cells
were stained with crystal violet, dissolved with 2% SDS, and quantified
spectrophotometrically at 550 nm using a SpectraMAX 340pc
(Molecular Devices, Sunnyvale, CA, www.moleculardevices.com)
plate reader. Results show relative adhesion measured after subtracting
the background absorbance from all values.Cell Migration Assays
Cell migration assays were performed using laminin-coated Transwell
chambers. The upper chamber medium consisted of neurosphere
culture medium without epidermal growth factor/fibroblast growth
factor, and the lower chamber medium consisted of Dulbecco’s
modified Eagle’s medium (DMEM) with 10% FBS. After 8 hours,
cells that had migrated through the filter were fixed and stained with
Hoechst 33342 (Life Technologies). Migration was quantified by
counting cells from eight random fields. Migration of glioma cells was
also quantified using a directional migration assay using a multiwell
nanopatterned device, consisting of parallel nanoridges/grooves of 400
nm in groove width, 400 nm in ridge width, and 500 nm in depth,
constructed of transparent poly(urethane acrylate) and fabricated using
UV-assisted capillary lithography as previously described [22,23]. Before
plating cells, nanogrooved substrata were coated with poly-D-ornithine(10-μg/ml concentration) for 15 minutes and laminin (3 μg/cm2)
overnight. These topographically patterned cell substrata cause cells to
align with and move along the direction of the nanogrooves. Cell
migration was quantified using time-lapse microscopy and a motorized
inverted microscope (Olympus IX81) equipped with a Cascade 512B II
CCD camera and temperature- and gas-controlling environmental
chamber. Phase-contrast cell images were automatically recorded under
4*1.6× objective using the Slidebook 4.1 (Intelligent Imaging
Innovations, Denver, CO) for 10 hours at 10-minute intervals as
previously published by us [13,14,17,25,30,46,62]. A custom-made
MATLAB script was used to calculate cell speed using time-lapse
microscopy data as described previously [1,17,25,30]. The average
speeds of individual cells were calculated from the total distance moved
throughout the entire cell trajectory and total recording time.
Tumor Implantation and Animal Treatments
All animal protocols were approved by the Johns Hopkins School
of Medicine Animal Care and Use Committee. For subcutaneous
(s.c.) xenografts, female athymic nude mice were injected s.c. in the
flank with 5 × 106 viable neurosphere cells (determined by Trypan
blue exclusion) in 0.1 ml of DMEM. When tumors reached about
50 mm3, mice were randomly divided into groups for treatment.
Dox was administered in animal feed. Tumor sizes were determined
daily by measuring two dimensions (length [a] and width [b]), and
volumes (V) were calculated using the formula V = ab2/2 [26].
For intracranial (i.c.) xenografts, severe combined immunodefi-
ciency (SCID) mice received 5000 viable neurosphere cells in 2 μl of
DMEM by stereotactic injection to the right caudate/putamen
(anterior-posterior = 0 mm, mesial-lateral = −2.5 mm, dorsal-ventral =
−3.0 mm). Mice were perfused with 4% paraformaldehyde at the
indicated times, and the brains were removed for histological analysis.
Tumor sizes were quantified bymeasuring maximum tumor volume on
hematoxylin and eosin–stained brain coronal sections using computer-
assisted morphometry (MCID software).
Quantitative Real-Time PCR (qRT-PCR)
Total RNA was extracted using Rneasy Mini Kit (Qiagen, Venlo,
Limburg, www.qiagen.com). After reverse transcription using MuLV
reverse transcriptase (Applied Biosystems, Calsbad, CA, www.
appliedbiosystems.com) and Oligo(dT) primer, qRT-PCR was
performed using SYBR Green PCR Mix (Applied Biosystems) and
IQ5 detection system (Bio-Rad, Hercules, CA, www.bio-rad.com).
Primer sequences are listed in Supplementary Table S1. Relative gene
was normalized to 18S rRNA.
Statistical Analysis
Statistical analysis was performed using Prizm software (GraphPad, La
Jolla, CA, www.graphpad.com). Post hoc tests included the Student’s t test
and Tukey multiple comparison tests as appropriate. All data are
represented as mean value ± SEM unless otherwise indicated.
Results
High Expression of CD151 in Aggressive Glioma Subtypes
and GSCs
TheRepository forMolecular BrainNeoplasiaData (REMBRANDT)
database (National Cancer Institute, https://caintegrator.nci.nih.gov/
rembrandt/), representing 28 nonneoplastic brain and 443 glioma tissue
samples, was used to compare the expression profile of CD151 in normal
brain and glioma tissues. CD151 expression was found to be 4.9-, 2.1-,
Figure 1. CD151 is highly expressed in glioma and GSCs.(A) CD151 mean gene expression intensity from REMBRANDT database (*,#P b
.0001 compared with nonneoplastic brain or GBM, respectively). CD151 expression is significantly upregulated in glioblastoma multiforme
(GBM) sampleswhen comparedwith nonneoplastic brain, oligodendroglioma, or astrocytoma samples. (B andC) Kaplan-Meier survival plots
for gliomapatients basedondifferential geneexpressionofCD151 fromREMBRANT (B) and TCGA (C) databases. Theprobability of survival is
significantly lower in samples with high CD151 gene expression compared with samples with intermediate expression in all glioma, GBM,
astrocytoma, and oligodendroglioma samples. For REMBRANDT comparisons, high CD151 gene expression samples were up at least
two-fold in all glioma, astrocytoma, and oligodendroglioma samples and at least six-fold in GBM compared with intermediate samples.
Inclusion of patients with low CD151 expression was not possible because of insufficient sample size. For TCGA comparisons, high CD151
expression samples were at least three-fold higher and low samples not more than three-fold lower than intermediate samples. (D)
Fluorescent photomicrography of GBM1B neurospheres permeabilized with Triton X-100 and immunostained using anti-CD151 antibody
(green fluorescence). Blue fluorescence indicates 4',6-diamidino-2-phenylindole) (4',6-diamidino-2-phenylindole (DAPI) nuclear stain (bar =
10 μm). (E) Membrane and cytoplasmic protein fractions isolated from GBM neurosphere lines (GBM1A, GBM1B) and primary GBM
neurosphere (612) were subjected to immunoblot analysis with anti-CD151 antibody. CD151 localizes tomembrane but not the cytoplasm of
glioma stem cells. (F) GBM1A neurosphere cells expressing undetectable and high levels of CD133 (CD133− and CD133+, respectively)
were separated by flow cytometry. qRT-PCR analysis shows that CD151mRNA expression is significantly higher in CD133+ cells (*P b .01).
(G) CD151 expressionwas analyzedbyqRT-PCR inGBM1AandGBM1Acells overexpressing stemness-driving transcription factorsOct4 and
Sox2 (GBM1A Oct4/Sox2). CD151 mRNA expression is higher in GBM1A Oct4/Sox2 cells compared with GBM1A cells. *P b .05.
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Figure 2. CD151 knockdown and transgenic CD151 expression in glioma neurospheres.(A–C) GBM neurospheres (GBM1A and GBM1B)
were infected with lentivirus coding for control shRNA, CD151 shRNA 1, or CD151 shRNA 2 (sequences provided in Supplemental Table 1).
CD151 expression was quantified by (A) immunoblot analysis of membrane protein collected 72 hours later using anti-CD151 antibody and
(B) qRT-PCR analysis of whole cell mRNA. (C) Neurosphere cells were analyzed by flow cytometry 6 days after transduction with lenti-CD151
shRNAusingCD151antibodies and isotype IgGcontrol. CD151knockdownsignificantly reduced thenumber ofCD151+cells. Representative
histograms and the percentages of CD151+ cells are shown. (D and E) GBM-derived neurosphere cells expressing a Dox-inducible
3FLAG-tagged CD151 (GBM1A 3F-CD151 andGBM1B 3F-CD151) were treated±Dox for 48 hours. 3Flag-CD151 expressionwas analyzed by
qRT-PCR using CD151-specific primers (D) and immunoblot of cell membrane fractions using anti-Flag (E). *P b .001.
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compared with nonneoplastic brain samples, and 2.3- and 2.4-fold higher
in GBM samples compared with oligodendroglioma and astrocytoma
samples, respectively (Figure 1A).
To investigate potential correlations between CD151 expression
and clinical outcome, we analyzed the prognostic significance ofCD151 in the REMBRANDT samples using Kaplan-Meir survival
curve analysis with log-rank comparisons. Survival for patients
expressing upregulated CD151 was significantly shorter compared
with that in those with intermediate expression in all glioma and
specific glioma subtypes (P b .001, P = .008, P = .027, and P = .012
in all glioma, GBM, oligodendroglioma, and astrocytoma samples,
Figure 3. CD151 regulates GSC self-renewal,(A and B) GBM neurosphere lines (GBM1A, GBM1B, P146) and primary GBM neurospheres
(612) were infected with lentivirus coding for control shRNA, CD151 shRNA 1, or CD151 shRNA 2. Equal numbers of viable cells were
plated and cultured for 14 days posttransduction to allow neurosphere formation. (A; bar = 100 μm) Representative microscopic images
of GBM1B neurospheres with control or CD151 shRNA are shown. (B) Neurospheres (N100 μm diameter) were counted. CD151 silencing
inhibited neurosphere formation in all neurosphere isolates examined. (C) Equal numbers of GBM1A 3F-CD151 and GBM1B 3F-CD151
neurosphere cells were plated and cultured for 7 days ± Dox under neurosphere growth conditions. Neurospheres (N100 μm diameter)
were quantified. CD151 overexpression increased neurosphere formation. (D and E) GBM1A, GBM1B, M1123, and 612 neurosphere cells
infected with lentivirus coding for control shRNA, CD151 shRNA 1, or CD151 shRNA 2 and cultured under neurosphere growth conditions.
Dissociated cells were stained with Trypan blue, and both viable (unlabeled) and nonviable (labeled) cells were counted on the days indicated
posttransduction. CD151 knockdown inhibited cell growth (D) but did not alter cell viability (E). *P b .05 compared with controls.
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CD151-expressing tumors were insufficient to compare with other
groups. A similar statistically significant correlation between high
CD151 expression and poor survival was identified using The Cancer
Genome Atlas (TCGA) glioblastoma dataset (National Cancer
Institute, https://tcga-data.nci.nih.gov/tcga) (Figure 1C).We examined CD151 expression in GBM-derived neurosphere lines
(GBM1A and GBM1B) and low passage GBM-derived primary neuro-
spheres (612) enriched inGSCs. Immunostaining readily detected CD151
expression (Figure 1D) that was found by immunoblot to localize to
membrane but not cytoplasmic fractions inmultipleGSC lines (Figure 1E).
CD151 expression was further examined by qRT-PCR analysis of
Figure 4. CD151 expression regulates expression of GSC markers and transcription factors.(A–D) GBM1A and GBM1B neurospheres
were infected with lentivirus coding for control shRNA, CD151 shRNA 1, or CD151 shRNA 2. (A and B) GBM1A and GBM1B cells were
analyzed by flow cytometry 6 days posttransduction using anti-CD133 and isotope IgG control. A representative histogram and the
percentages of CD133+ cells are shown. CD151 silencing decreased the number of CD133+ cells. Total cell lysates were analyzed by
immunoblot (C) and by qRT-PCR (D) for Sox2 and Olig2 expression. CD151 inhibition decreased expression of Sox2 and Olig2. (E and F)
GBM1A 3F-CD151 and GBM1B 3F-CD151 neurospheres expressing Dox-inducible 3Flag-CD151 were treated ± Dox. Whole cell extracts
were analyzed by immunoblot for Olig2 and Sox2 (E). Transgenic CD151 expression promoted Olig2 expression in both cells and Sox2
expression in GBM1B 3F-CD151 GSCs. Analysis of Sox2, and Olig2 expression by qRT-PCR shows that CD151 promoted mRNA
expression of the stemness-driving transcription factors (F).
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represent GBM-propagating stem cells [45]. CD151 expression was
elevated in CD133+ cells relative to CD133− cells (Figure 1F).
To further study the association of CD151 with cell stemness and
stemness-driving transcription factors, CD151 expression was
analyzed using qRT-PCR in GBM-derived neurospheres engineered
to overexpress Oct4 and Sox2 (GBM1A Oct4/Sox2). Co-expressing
transgenic Oct4 and Sox2, previously shown by us to induce
tumor-propagating GSCs [34], increased CD151 expression three-
fold (Figure 1F). These results show that CD151 is upregulated in the
most aggressive gliomas and that CD151 upregulation is associated
with poor prognosis independent of glioma grade. CD151 expression
is also highly upregulated in glioma-propagating stem cells.Regulation of GSC Self-Renewal by CD151
Gain- and loss-of-function approaches were used to evaluate the
effects of CD151 expression in GSCs. Transduction of GBM-derived
neurospheres with lentivirus coding for CD151 shRNAs (CD151
shRNA 1 and CD151 shRNA 2) significantly inhibited CD151
protein and mRNA expression (Figure 2, A and B) and decreased the
number of CD151+ cells by up to 99% (Figure 2C). We also
engineered three independent neurosphere lines to express a
Dox-inducible N-terminal 3xFLAG-tagged CD151 transgene
(3F-CD151; designated as GBM1A 3F-CD151, GBM1B
3F-CD151, and 612 3F-CD151). Dox treatment for 48 hours
induced expression of CD151 mRNA and membrane-associated
CD151 protein (Figure 2, D and E).
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proliferation were examined. Self-renewal as measured by neurosphere
formation was markedly inhibited by CD151 expression knockdown
(61% to 96% inhibition) inmultiple lines and primary isolates, including
neurospheres derived frommesenchymal (M1123) and proneural (P146)glioblastoma subtypes (Figure 3, A and B; Fig. S1). Conversely, forced
CD151 expression significantly increased neurosphere formation
(Figure 3C). Silencing CD151 expression impaired neurosphere cell
proliferation from34% to 63% (Figure 3D). CD151 knockdown did not
induce detectable cell death (Figure 3E).
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by CD151
We investigated the effect of CD151 silencing on the expression of
markers and regulators of GBM cell stemness. CD151 knockdown in
neurospheres reduced the number of CD133+ cells by 32% to 52%
(Figure 4, A and B). GSCs are regulated by stemness-associated
transcription factors, including Olig2 and Sox2 [16,31,34]. CD151
silencing decreased Sox2 and Olig2 expression as evidenced by
reductions in both cellular RNA and protein (Figure 4, C and D).
Conversely, there was a variable but strong trend of increased Olig2
and Sox2 expression in response to forced CD151 expression
(Figure 4, E and F).Inhibition of GBM Neurosphere Cell Adhesion and Migration
by CD151 Targeting
GBM-derived neurosphere cells transduced with control lentivirus
or with lentiviral vectors engineered to express either CD151 shRNA
were seeded on laminin-coated Transwell membranes to evaluate
migration capacity. CD151 silencing reduced migration by 47% to
87% (Figure 5, A and B). Conversely, forced CD151 expression
enhanced cell migration on laminin-coated Transwells by 42% to
109% (Figure 5C).
The glioma microenvironment constitutes a physically and
chemically diverse terrain that influences cell migration. Specifically,
glioma cells preferentially migrate along structured pathways such as
myelinated neuronal tracts and blood vessels [4]. To further study the
effect of CD151 on architecturally directed GSC migration, neuro-
sphere cells transfected with control or CD151 shRNA lentivirus
were seeded on a laminin-coated substrate consisting of linear
nanoscale grooves. Migration along the nanoscale grooves enables a
more precise assessment of migration parameters such as cell speed
and distance traveled over several hours. CD151 silencing signifi-
cantly reduced average cell migration speed by 41% to 57% (Figure 5,
D and E; Video S1). In addition, control shRNA transfected cells
showed a higher percentage of cells migrating at maximum speeds
than CD151 shRNA transfected cells (Figure 5F). CD151
knockdown also reduced the average distance migrated over 10
hours (Figure 5, G and H).
Cell adhesion events impact cell migration capacity. To determine
if CD151 modulates neurosphere cell adhesion, GBM-derived
neurosphere cells transduced with control lentivirus or lentivirus
coding for CD151 shRNA were seeded on a laminin-coated substrata.
CD151 silencing delayed the rate of cell adhesion and spreadingFigure 5. CD151 regulates GBM neurosphere cell adhesion and migra
transducedwith lentivirus coding either for control shRNA,CD151 shRNA
24 hours) were plated on laminin-coated Transwell membranes, and tr
DAPI-stained cells. Representative microscopic fields of GBM1B neuro
shown (A; bar = 50 μm). Cells per field were counted (B and C). CD151
migration. (D–J) GBM neurospheres (GBM1A, GBM1B, M1123, 612) in
CD151 shRNA 2 cDNA. 612cells were plated on laminin-coated multiw
customMATLAB program. Average cell speeds at each indicated time p
(E) are shown. A histogram of average speed for individual cells is sh
(G). Representative trajectories of cells transduced with control shRNA
(red dots) and final locations at 10 hours (blue dots) of individual cells are
Control cells migrated faster and farther than CD151 shRNA transduce
substrata for 2 and 6 hours. Cell adhesion and morphology were evalua
spectrophotometric analysis of crystal violet–stained cells (J). CD151 sil
3F-CD151, GBM1B 3F-CD151, and 612 3F-CD151 neurospheres were tr
evaluated by spectrophotometric analysis of crystal violet–stained cells 2
expression promoted adhesion 6 hours after seeding. * P b .05 compar(Figure 5, I and J). Forced CD151 expression had no effect on cell
adhesion when evaluated 2 hours after seeding on a laminin-coated
surface but significantly increased adhesion after 6 hours (Figure 5K).
Collectively, the data indicate that CD151 regulates neurosphere cell
adhesive and migratory interactions with laminin-containing matrices.Regulation of GBM Neurospheres by
CD151-Integrin Interactions
CD151 complexes with laminin-binding integrins and influ-
ences integrin-driven biological processes in several cell types [47,53].
Integrins are also highly expressed in stem cells, including GSCs, and
thought to contribute to stemness by modulating interactions with
micoenvironmental niches [6,27]. Immunofluorescent staining
showed that CD151 colocalizes with integrins α3, α6, and β1 in
the plasma membrane of GBM neurosphere cells (Figure 6A). To
further investigate CD151’s association with integrins, GBM1A
3F-CD151 neurosphere cells were treated ± Dox for 48 hours to
induce CD151 expression. CD151 immunoprecipitation using
anti-FLAG co-precipitated integrins α3, α6, and β1 (Figure 6B).
Neither forced expression of CD151 nor knockdown of endogenous
CD151 altered levels of membrane-associated cell surface integrins
α6 and β1 (Figs. S2 and 3).
We investigated the effect of CD151 expression on activation of
integrin signaling in GBM neurosphere cells. CD151 knockdown
reduced serine473 Akt phosphorylation, a downstream effector of
integrin signaling that promotes various biological processes including
survival and cell motility [7], whereas forced CD151 expression
enhanced Akt phosphorylation (Figure 6, C and D).
The anti-CD151 antibody TS151r, previously shown to specifi-
cally block interactions between CD151 and integrins α3 and α6
[21,41,47,57], was used to determine if CD151-integrin interactions
modulate GSC behavior. Incubating cells with TS151r mimicked
CD151 expression knockdown by multiple criteria. TS151r inhibited
self-renewal as spheres by 77% to 95% (Figure 6E), reduced cell
migration on laminin by 70% to 75% (Figure 6F), and inhibited Akt
phosphorylation (Figure 6G). We examined the effect of the Akt
inhibitor MK-2206 on the stimulation of GSC migration by CD151
to further examine the role of Akt activation as a downstream effector
of CD151-mediated cell responses. MK-2206 was found to reverse
GSC migration induction by Dox-inducible CD151 (Figure 6H).
Taken together, the results strongly support a mechanism by which
CD151-laminin interactions support GSC self-renewal and migra-
tion by altering integrin function and downstream Akt signaling.tion.(A–C) GBM neurospheres (GBM1A, GBM1B, P146, M1123, 612)
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Figure 6. CD151:integrin complexes regulate neurosphere cell self-renewal, migration, and Akt activation.(A) GBM1A neurosphere cells
collected by cytospin were co-immunostained with antibodies against CD151 and either integrin α3, integrin α6, or integrin β1 (bar =
10μm). CD151 distribution overlaps with the integrins. (B) GBM1A 3F-CD151 cells were treated ± Dox for 48 hours. Brij-O1 collected
protein lysates subjected to immunoprecipitation with anti-FLAG specifically precipitated 3F-CD151, integrin α3, integrin α6, and integrin
β1 proteins. (C) GBM neurosphere lines GBM1A and GBM1B were infected with lentivirus coding for control shRNA, CD151 shRNA 1, or
CD151 shRNA 2. Total cell lysates were extracted and analyzed by immunoblot using antibodies against S473 phosphorylated Akt (pAkt)
and total Akt (tAKT). CD151 inhibition decreased Akt phosphorylation. (D) GBM1A 3F-CD151 and GBM1B 3F-CD151 neurospheres were
treated ± Dox. Whole cell extracts were analyzed by immunoblot for pAkt and tAkt. Forced CD151 expression promoted Akt
phosphorylation. (E–G) GBM1A and GBM1B cells were treated with anti-CD151 antibody TS151r, which blocks integrin α3 and α6 binding.
Isotype IgG was used as control. (E) Equal numbers of viable cells were cultured in 48-well plates with TS151r antibody (or IgG control)
for 14 days to form neurospheres. Neurospheres (N50 μm diameter) were counted. Neurosphere formation was inhibited by TS151r.
(F) Neurosphere cells were plated on laminin-coated Transwell membranes. Migration was evaluated 8 hours later by counting
DAPI-stained cells. Cells per field were counted. TS151r inhibited migration on laminin. (G) Whole cell lysates were collected and
subjected to immunoblot analysis for pAkt and tAkt. CD151 knockdown inhibits Akt phosphorylation. (H) GBM1A 3F-CD151 cells were
treated ± Akt inhibitor MK-2206 (5 μM, Selleckhem, Houston TX) for 1 hour followed by ± Dox for 24 hours to induce 3F-CD151.
Neurosphere cells were plated on laminin-coated Transwell membranes. Migration was evaluated 8 hours later by counting DAPI-stained
cells. Cells per field were counted. Akt inhibition abrogated CD151-induced cell migration. *P b .01.
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GBM Xenografts by CD151 Silencing
We examined the effects of CD151 silencing on the growth of s.c.
and i.c. xenografts established from GBM-derived neurospheres.
Subcutaneous xenografts were established in mice with M1123neurosphere cells engineered to express a Dox-inducible CD151
shRNA (M1123 CD151 shRNA). Beginning on postimplantation day
(PID) 8, mice were randomly assigned to control or Dox-treated
groups. Tumors were then measured through PID 15 to monitor the
effects of CD151 silencing. Average tumor size increased from 74 to
Figure 7. CD151 knockdown inhibits the growth of neurosphere-derivedGBMxenografts.(A andB)Micewere implanted subcutaneouslywith
Dox-inducibleM1123CD151 shRNA cells.Micewere started on aDox-containingdiet on PID 8, and tumorsweremeasureddaily as described
in “Materials and Methods” (A). CD151 knockdown inhibited xenograft growth. Immunoblot analysis of total protein extracts from
subcutaneous xenografts obtainedonPID15 confirm in vivoDox-inducedCD151knockdown (B). (CandD)GBM1Acellswere transducedwith
lentivirus coding for control shRNA or CD151 shRNA cDNA. After 24 hours, 5000 viable cells were implanted by stereotactic injection to
caudate/putamenof SCIDmice. Hematoxylin and eosin–stainedcoronal brain sections (20μm) obtained fromanimals onPID 52 are shown (C;
bar= 1mm). Quantification of xenograft tumor volume shows that silencingCD151 repressed xenograft growth (D;Pb .001). (E) 10,000 viable
GBM1B-GFP control cells and 10,000 viable GBM1BRFP-taggedDox-inducible CD151 shRNA cells were co-implanted to caudate/putamen of
SCIDmice. Animals were started on a Dox-containing diet on PID 8 and sacrificed on PID45. Immunofluorescent images of brain sections are
shown. The white arrows indicate GBM1B CD151 shRNA cells.
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mice. By PID 15, CD151 shRNA had inhibited tumor growth by 71%
(Figure 7A). CD151 knockdown in vivowas confirmed by immunoblot
of whole tumor protein extracts using CD151 antibody (Figure 7B).To examine the effect of CD151 silencing on i.c. tumor
formation, GBM1A cells were transfected with control lentivirus
or with lentivirus expressing CD151 shRNA. Viable cells were
implanted 24 hours later into the brains of SCID mice. Mice were
196 Regulation of Glioblastoma Tumor-Propagating Cells Tilghman et al. Neoplasia Vol. 18, No. 3, 2016sacrificed 52 days later, and coronal brain sections were examined for
tumor size. Tumor formation was significantly reduced in mice
implanted with CD151 shRNA-treated cells (19.1 ± 3.9 mm3 max
tumor volume) compared with control shRNA tumors (54.3 ± 5.0 mm3
max tumor volume) (Figure 7, C and D).
To further determine the effect of CD151 silencing on tumor
formation, GFP-tagged GBM1B control cells and RFP-tagged
GBM1B Dox-CD151 shRNA cells were co-implanted to mouse
brains. The mice were then treated with Dox for 45 days post–cell
implantation. Immunoflourescent imaging of brain sections revealed
a marked inhibition of the RFP-tagged CD151 knockdown cells
compared with the GFP-tagged controls (Figure 7E).Discussion
Despite recent substantive advances in our understanding of basic
cancer mechanisms and their clinical translation, there have been only
marginal improvements in the survival of patients with glioblastoma
multiforme. This is due at least in part to the specialized biology of
glioma-propagating cancer stem cells (GSCs), their resilience in the
face of cancer therapies, and their contributions to tumor recurrence.
This paper identifies CD151 and its direct interactions with integrins
as regulators of GSC stemness and tumorigenicity.
Using multiple approaches, we show that CD151 associates with
and actively regulates GSCs and the growth of GBM xenografts
derived from GSCs. Glioma neurosphere cells expressing the
stemness marker CD133 were found to express high levels of
CD151 compared with CD133-negative cells, and silencing CD151
blocked glioma cell capacity to self-renew as spheres, impaired
proliferation, and inhibited expression of markers and drivers of cell
stemness including CD133, Sox2, and Olig2. Alternatively, CD151
expression was increased in CD133-positive cells following forced
expression of the Oct4 and Sox2 transcription factors under
conditions that induce glioma-propagating cells [34]. Conversely,
forcing the expression of CD151 enhanced glioma cell self-renewal
and increased expression of stemness-associated factors. These
findings demonstrate a strong mechanistic link between CD151
expression and GSC stemness and provide a novel functional context
to our recent report showing that CD151 resides within a
transcriptional network that is repressed by KLF9, a transcription
factor that induces GSC differentiation and inhibits GSC tumor-
propagating potential. Our data extend and provide a functional
context to previous studies from other investigators in different organ
systems showing an association of CD151 expression with the
capacity of prostate cancer cells to self-renew as spheres [39] and the
CD151-dependent regulation of progenitor cell pools during
mammary development [58].
Our results point to a cooperative role for the integrin family of cell
adhesion receptors that mediate cell-cell and cell–extracellular matrix
adhesion interactions and intracellular signaling responses in the
mechanism by which CD151 regulates GSCs. Integrins interact with
ligands in the extracellular matrix to bidirectionally transduce signals
that modulate biological processes, including adhesion and migra-
tion [3]. Integrins are also highly expressed in nonneoplastic and
neoplastic stem cells and appear to support the stem cell phenotype
via interactions with stemness-promoting stromal niches [6,27]. The
laminin-binding integrin receptor subunits α3, α6, β1, and β4 in
particular have been shown to support GSC stemness. Integrin α3 isupregulated in GSCs and contributes to GSCmigration and invasion
[36]. Integrin α6 has been found to mark GSCs and regulate GSC
self-renewal and tumor-propagating capacity [27].We now show that
CD151 directly complexes with integrin receptor subunits α3, α6,
and β1 in GBM neurosphere cells and that cell responses activated by
forced CD151 expression (i.e., self-renewal as spheres and Akt
activation) are inhibited by blocking the CD151-integrin interac-
tion. These findings complement previous studies in other cell
models showing that CD151 forms tight complexes with laminin-
binding integrins and influences activation of downstream integrin
signaling [19,21,43,47,57]. For example, CD151’s interaction with
integrins α3 and α6 are maintained under stringent lysis conditions
(Triton X-100 or NP-40) in melanoma, hepatocellular carcinoma,
and endothelial cells [12,19,32]. Liu et al. [32] also showed that
overexpression of CD151 activates several downstream proteins in
the integrin signaling pathway including FAK, PI3K, Akt, ERK1/2,
cdc42, and Rac1 in endothelial cells. Interestingly, we previously
found that the transcription factor KLF9, which inhibits GSC
stemness and GBM xenograft propagation, represses the expression
of both ita6 (integrin α6) and CD151[59]. Thus, CD151 and
integrin α6 are co-regulated within a transcriptional network that
regulates GSC stemness and glioma propagation.
A prominent feature of clinical gliomas and GSCs is their capacity
to invade surrounding brain [42], and CD151 has been shown to
promote the adhesion and migratory capacity of several cancer cell
types [10,12,24,53,55]. We now show that CD151 stimulates GBM
neurosphere cell migration and the rate of neurosphere cell adhesion
to integrin-binding substrata. Our data showing that blocking
CD151 binding to integrins α3 and α6 inhibits neurosphere cell
migration on laminin complement the findings of Fei et al. [12] who
found that transfecting hepatocellular carcinoma cells with pAAV-C-
D151-AAA, which codes for a mutant CD151 deficient in
integrin-binding capacity, inhibits invasion. Similarly, pAAV-C-
D151-AAA has been shown to inhibit CD151-promoted cell
migration in prostate cancer cells [54].
In conclusion, we show that CD151 supports GBM cell stemness
and self-renewal and that inhibiting CD151 expression in vivo
impedes experimental GBM growth. Our findings directly implicate
CD151 binding to integrins α3 and α6 and Akt activation induced
by CD151-integrin complex formation in CD151’s oncogenic
activities. These previously unrecognized CD151 functions suggest
alternative approaches to integrin-targeting glioma therapeutics that
may be limited by integrin expression on normal neural cells. Our
findings support efforts to develop clinically translatable inhibitors of
CD151 and CD151-integrin interactions as a potential strategy for
targeting GBM tumor-propagating cells and their derivative
malignancies.
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